Trial ID: | L1187 |
Source ID: | NCT00506454
|
Associated Drug: |
Lipidose
|
Title: |
Lipid Infusion in Dialysis Patients With Endotoxemia
|
Acronym: |
LIPIDOSE
|
Status: |
COMPLETED
|
Study Results: |
YES
|
Results: |
https://ClinicalTrials.gov/show/NCT00506454/results
|
Conditions: |
Fatigue|End Stage Renal Disease (ESRD)
|
Interventions: |
DRUG: Lipidose|DRUG: Placebo
|
Outcome Measures: |
Primary: Reduction in Endotoxin Levels., The number of participants whose post-hemodialysis endotoxin (as measured by Endotoxin Activity Assay (EAA)) was less than their pre-hemodialysis endotoxin., Baseline and at 4 weeks |
|
Sponsor/Collaborators: |
Sponsor: Sepsicure | Collaborators: The Rogosin Institute
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE2
|
Enrollment: |
22
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
Start Date: |
2007-08
|
Completion Date: |
2008-02
|
Results First Posted: |
2011-08-15
|
Last Update Posted: |
2011-09-20
|
Locations: |
Rogosin Manhattan Dialysis Center, New York, New York, 10021, United States
|
URL: |
https://clinicaltrials.gov/show/NCT00506454
|